Rafarma Pharmaceuticals, Inc. (RAFA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 75 | 77 | 64 | 10 | 9 | 9 | 9 | - |
| Operating profit | $m | 0 | 0 | ||||||
| Net profit | $m | 15 | 12 | 5 | 0 | 0 | 0 | 0 | - |
| EPS reported | $ | 0.00 | 0.00 | ||||||
| Operating cashflow per share | $ | 0.00 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | 0.00 | ||||||
| Free cash flow | $m | -0 | 0 | ||||||
| Net debt | $m | -0 | -0 | ||||||
| Book value equity | $m | 10 | 10 | ||||||
| Book value per share | $ | 0.12 | 0.12 | ||||||
| Number of shares | m | 87.77 | 87.77 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 6.86 | - | ||||||
| P/B LTM | x | 0.23 | 0.23 | ||||||
| P/S LTM | x | 0.26 | 0.27 | ||||||
| P/FCF LTM | x | -150.44 | 2,407.01 | ||||||
| EV/EBITDA LTM | x | 4.85 | 5.63 | ||||||
| EV/Sales LTM | x | 0.26 | 0.35 | ||||||
| Earnings Yield LTM | % | +14.58% | +6.80% | ||||||
| FCF Yield | % | -0.66% | +0.04% | ||||||
| Quality | |||||||||
| ROE | % | +3.32% | +2.00% | ||||||
| ROIC | % | +3.80% | +2.65% | ||||||
| Operating margin | % | +5.33% | +3.85% | ||||||
| Gross margin | % | +8.29% | +6.18% | ||||||
| FCF/Sales | % | -0.17% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +33.33% | -23.33% | ||||||
| Sales Growth YoY | % | +1.09% | -1.44% | ||||||
| Net Income Growth YoY | % | +31.20% | +8.65% | ||||||
| FCF Growth | % | - | -97.73% | ||||||
| Operating Profit Growth | % | +20.74% | +3.95% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.70 | 0.05 | ||||||
| Net Debt/EBITDA | x | -0.07 | -0.11 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.96% | +0.72% | ||||||
| Net debt/Equity | x | -0.00 | -0.00 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Rafarma Pharmaceuticals, Inc. (RAFA)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free